SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-070191
Filing Date
2024-03-18
Accepted
2024-03-18 16:31:02
Documents
15
Period of Report
2024-03-12
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d691064d8k.htm   iXBRL 8-K 27684
2 EX-4.1 d691064dex41.htm EX-4.1 83537
6 GRAPHIC g691064dsp06.jpg GRAPHIC 2061
  Complete submission text file 0001193125-24-070191.txt   259812

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20240312.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20240312_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20240312_pre.xml EX-101.PRE 11262
18 EXTRACTED XBRL INSTANCE DOCUMENT d691064d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 24759497
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)